Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma

被引:72
作者
Drakos, Elias
Thomaides, Athanasios
Medeiros, L. Jeffrey
Li, Jiang
Leventaki, Vasiliki
Konopleva, Marina
Andreeff, Michael
Rassidakis, George Z.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA
关键词
D O I
10.1158/1078-0432.CCR-06-2581
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: p53 is frequently expressed but rarely mutated in Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin's lymphoma (HL). p53 protein levels are regulated by murine double minute 2 (MDM2) through a well-established autoregulatory feedback loop. In this study, we investigated the effects of nutlin-3A, a recently developed small molecule that antagonizes MDM2 and disrupts the p53-MDM2 interaction, on p53-dependent cell cycle arrest and apoptosis in cultured FIRS cells. Experimental Design: HL cell lines carrying wild-type (wt) or mutated p53 gene were treated with the potent MDM2 inhibitor nutlin-3A or a 150-fold less active enantiomer, nutlin-3B. Results: We show that nutlin-3A, but not nutlin-3B, stabilizes p53 in cultured HRS cells carrying wt p53 gene resulting in p53-dependent cell cycle arrest and apoptosis. Cell cycle arrest was associated with up-regulation of the cycl in-dependent kinase inhibitor p21. Nutlin-3A-induced apoptotic cell death was accompanied by Bax and Puma up-regulation and caspase-3 cleavage and was abrogated, in part, by inhibition of caspase-9 and caspase-3 activity. By contrast, no effects on cell cycle or apoptosis were found in HL cell lines harboring mutated p53 gene. Furthermore, combined treatment with nutiin-3A and doxorubicin revealed enhanced cytotoxicity in HRS cells with wt p53 gene. Blocking of nuclear export by leptomycin B, or inhibition of proteasome by MG132, stabilized p53 at a level comparable with that of nutlin-3A treatment in HRS cells with wt p53. Conclusions: These data suggest that nutlin-3A stabilized p53 by preventing MDM2-mediated p53 degradation in HRS cells. wt p53 stabilization and activation by nutlin-3A may be a novel therapeutic approach for patients with HL.
引用
收藏
页码:3380 / 3387
页数:8
相关论文
共 44 条
[1]   Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin lymphoma study group [J].
Behringer, K ;
Josting, A ;
Schiller, P ;
Eich, HT ;
Bredenfeld, H ;
Diehl, V ;
Engert, A .
ANNALS OF ONCOLOGY, 2004, 15 (07) :1079-1085
[2]   Second cancers after pediatric Hodgkin's disease [J].
Bhatia, S ;
Meadows, AT ;
Robison, LL .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2570-2571
[3]   p53 ubiquitination: Mdm2 and beyond [J].
Brooks, CL ;
Gu, W .
MOLECULAR CELL, 2006, 21 (03) :307-315
[4]   CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J].
CANELLOS, GP ;
ANDERSON, JR ;
PROPERT, KJ ;
NISSEN, N ;
COOPER, MR ;
HENDERSON, ES ;
GREEN, MR ;
GOTTLIEB, A ;
PETERSON, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) :1478-1484
[5]   Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors [J].
Carvajal, D ;
Tovar, C ;
Yang, H ;
Vu, BT ;
Heimbrook, DC ;
Vassilev, LT .
CANCER RESEARCH, 2005, 65 (05) :1918-1924
[6]  
Chen WG, 1996, LAB INVEST, V75, P519
[7]   Second malignancies after chemotherapy and radiotherapy for Hodgkin disease [J].
Chronowski, GM ;
Wilder, RB ;
Levy, LB ;
Atkinson, EN ;
Ha, CS ;
Hagemeister, FB ;
Barista, I ;
Rodriguez, MA ;
Sarris, AH ;
Hess, MA ;
Cabanillas, F ;
Cox, JD .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (01) :73-80
[8]   MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells [J].
Coll-Mulet, Llorenc ;
Iglesias-Serret, Daniel ;
Santidrian, Antonio F. ;
Cosialls, Ana M. ;
de Frias, Merce ;
Castano, Esther ;
Campas, Clara ;
Barragan, Montserrat ;
Fernandez de Sevilla, Alberto ;
Domingo, Alicia ;
Vassilev, Lyubomir T. ;
Pons, Gabriel ;
Gil, Joan .
BLOOD, 2006, 107 (10) :4109-4114
[9]   RECENT RESULTS ON THE BIOLOGY OF HODGKIN AND REED-STERNBERG CELLS .2. CONTINUOUS CELL-LINES [J].
DREXLER, HG .
LEUKEMIA & LYMPHOMA, 1993, 9 (1-2) :1-25
[10]  
ElenitobaJohnson KSJ, 1996, AM J CLIN PATHOL, V106, P728